Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction

Circulation

Volumn 102, Issue 15, 2000, Pages 1766-1772

  Collen, Désiré ^a,c   Sinnaeve, Peter ^b   Demarsin, Eddy ^a   Moreau, Huberte ^a   De Maeyer, Marc ^a   Jespers, Laurent ^a   Laroche, Yves ^a   Van De Werf, Frans ^b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Fibrinogen; Myocardial infarction; Thrombolysis

Indexed keywords

CYSTEINE; FIBRINOGEN; MACROGOL DERIVATIVE; MALEIMIDE DERIVATIVE; RECOMBINANT ENZYME; STAPHYLOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANTIGEN RECOGNITION; ARTICLE; BLOOD CLOT LYSIS; CHEMICAL MUTAGENESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERIVATIZATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; FIBRINOGEN METABOLISM; FIBRINOLYTIC THERAPY; HUMAN; IMMUNOGENICITY; MALE; NONHUMAN; PLASMA CLEARANCE; PLASMA HALF LIFE; PRIORITY JOURNAL;

EID: 0034633820     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.15.1766     Document Type: Article

References (16)

1. Fibrin-selective thrombolytic therapy for acute myocardial infarction
2. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction
3. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double blind randomized trial
4. Staphylokinase: A potent, uniquely fibrin-selective thrombolytic agent
5. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction
6. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction: The STAR Trial Group
7. A pilot randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction
8. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes
9. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase
10. Biomedical and biotechnological applications of PEG- and PM-modified proteins
11. Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase
12. High yield production and purification of recombinant staphylokinase for thrombolytic therapy
13. Improved media for growing plasmid and cosmid clones
14. A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents
15. Recombinant staphylokinase variants with altered immunoreactivity, II: Thrombolytic properties and antibody induction